<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030667</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01869</org_study_id>
    <secondary_id>NCI-2012-01869</secondary_id>
    <secondary_id>CDR0000069187</secondary_id>
    <secondary_id>COG-ADVL0122</secondary_id>
    <secondary_id>ADVL0122</secondary_id>
    <secondary_id>ADVL0122</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00030667</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood</brief_title>
  <official_title>A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have&#xD;
      relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of&#xD;
      tumor cells by blocking the enzymes necessary for their growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate of patients with relapsed or refractory pediatric solid tumors&#xD;
      treated with imatinib mesylate.&#xD;
&#xD;
      II. Determine the toxicity of this drug in these patients. III. Determine the time to&#xD;
      progression in patients treated with this drug. IV. Determine the pharmacokinetics of this&#xD;
      drug in these patients. V. Correlate response with c-kit and platelet-derived growth factor&#xD;
      receptor expression in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to disease (Ewing's&#xD;
      sarcoma/primitive neuroectodermal tumor vs osteosarcoma vs neuroblastoma vs other).&#xD;
&#xD;
      Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat&#xD;
      every 28 days for up to 2 years in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate, determined using the RECIST criteria</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>95% confidence interval will be computed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity reported using the CTC version 2.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Calculated by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Childhood Desmoplastic Small Round Cell Tumor</condition>
  <condition>Childhood Synovial Sarcoma</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Lung Metastases</condition>
  <condition>Recurrent Childhood Soft Tissue Sarcoma</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumors including the following:&#xD;
&#xD;
               -  Ewing's sarcoma&#xD;
&#xD;
               -  Bone or soft tissue primitive neuroectodermal tumor&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Desmoplastic small round cell tumor&#xD;
&#xD;
               -  Synovial cell sarcoma&#xD;
&#xD;
               -  Gastrointestinal stromal tumor (GIST)&#xD;
&#xD;
          -  Metastatic pulmonary disease eligible&#xD;
&#xD;
               -  No pleural effusion of any size or definite radiologic evidence of pleural-based&#xD;
                  disease&#xD;
&#xD;
          -  Recurrent or refractory to conventional therapy&#xD;
&#xD;
               -  GIST eligible at initial presentation&#xD;
&#xD;
          -  Tumor tissue blocks must be available&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Lesions assessable only by radionuclide scan are not considered measurable&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (≤ 10 years of age)&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (&gt; 10 years of age)&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3* (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL* (RBC transfusions allowed)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  INR &lt; 1.5&#xD;
&#xD;
          -  PTT ≤ ULN&#xD;
&#xD;
          -  Fibrinogen ≥ lower limit of normal&#xD;
&#xD;
          -  Creatinine normal for age&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 70 mL/min&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  At least 1 week since prior biologic therapy or immunotherapy and recovered&#xD;
&#xD;
          -  At least 1 week since prior growth factors&#xD;
&#xD;
          -  No concurrent immunomodulating agents&#xD;
&#xD;
          -  At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 3 months since prior craniospinal radiotherapy or radiotherapy to 50% or more&#xD;
             of pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiation&#xD;
&#xD;
          -  No concurrent radiotherapy during first course of treatment&#xD;
&#xD;
          -  Concurrent palliative radiotherapy to local painful lesions allowed after first course&#xD;
             of treatment provided there is no evidence of disease progression and at least 1&#xD;
             measurable lesion remains outside radiation port&#xD;
&#xD;
          -  No concurrent therapeutic doses of warfarin&#xD;
&#xD;
          -  No concurrent anticonvulsants that induce the cytochrome p450 enzyme system (e.g.,&#xD;
             phenytoin, carbamazepine, and phenobarbital)&#xD;
&#xD;
          -  Concurrent benzodiazepines and gabapentin allowed&#xD;
&#xD;
          -  Concurrent low-molecular weight heparin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason Bond</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

